1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
63161A7F26BDE3E8D0025863900495621
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/3161A7F26BDE3E8D0025863900495621?OpenDocument
18
19OpenDocument
2035.170.64.36
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Digital Technology » Cross-Functional Digital Transformation

Pharma’s Digital Transformation Turning Point for Medical and Commercial Leaders: External Engagement, Virtual Advisory Boards and Clinical Trials

ID: 5654


Features:

16 Info Graphics

21 Data Graphics

330+ Metrics

32 Narratives


Pages/Slides: 45


Published: 2020


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Pharma’s Digital Transformation Turning Point for Medical and Commercial Leaders: External Engagement, Virtual Advisory Boards and Clinical Trials”

STUDY OVERVIEW

The global COVID-19 pandemic not only upended nearly every aspect of the biopharma engagement model but also sped up the long-awaited digital transformation of the industry. While many companies have accelerated their adoption of digital solutions, they continue to face numerous hurdles in transforming the business to better support healthcare stakeholders in the post-COVID world.

This Best Practices, LLC compendium draws upon 10 of our primary benchmark studies to uncover the most critical digital transformation strategies and programs being initiated across medical and commercial operational fronts in response to the COVID-19 pandemic.

This study probes the various approaches towards digital transformation adopted by forward-looking biopharma companies spanning critical areas including HCP and external engagement, virtual advisory boards, and clinical trials management. It spotlights the key challenges and recommendations for biopharma leaders seeking to maximize performance and aid the digital growth of their own organization.

KEY TOPICS

  • Virtual engagement with HCPs and external stakeholders
  • Virtual advisory boards
  • Managing clinical trials during and beyond the COVID-19 pandemic

KEY METRICS
  • Do you plan to use any of the listed technologies for external engagement during the COVID-19 pandemic?
  • Have virtual trials enabled your organization to overcome any of the listed challenges faced during on-site clinical trials?
  • Has your company implemented digital or non-digital remote alternatives to face-to-face interactions with any of the listed external groups?
  • How frequently are you using the various modes of technology to support external stakeholder communication?
  • For the time periods listed, indicate what percentage of your physician ad boards were/are being done live, virtual, and taped for on-demand?
  • Please identify the tools you are utilizing to improve virtual physician advisory boards and which is the most effective
  • How have the clinical trials timeline been impacted due to the additional safety protocols and monitoring processes?
  • Has your organization switched to remote assessment of the patients involved in a clinical trial since COVID-19?
  • How has the delay/halt in clinical trials impacted your organization financially?
  • What process do you follow to enroll patients virtually?
  • What benefits have you or your organization encountered in conducting virtual trials?

SAMPLE KEY FINDINGS
  • HCP and external engagement: Companies expect to permanently conduct 40% of their engagements virtually, even post-pandemic.

METHODOLOGY

This Best Practices, LLC compendium draws upon 10 of our primary benchmark studies of over 200 biopharma executives from 178 life sciences companies to reveal the most effective digital strategies, tools and approaches being implemented by forward-looking Medical and Commercial leaders.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Medical Device; Biopharmaceutical; Laboratories; Clinical Research; Manufacturing; Consumer Products; Consulting; Technology; Communications; Computer Software; Telecommunications; Research; Medical; Professional Services; Science; Marketing


Companies Profiled:
Abbott; AbbVie; ADC Therapeutics; Advanced Accelerator Applications; AeroGen; Inc.; Agios; Aimmune Therapeutics; Alcon Laboratories; Align Technology; Alkem; Alkermes; Allergan; Almirall; Alnylam Pharmaceuticals; AMAG Pharmaceuticals; Amgen; Amicus Therapeutics; Apellis Pharmaceuticals; Aptus Clinical; Arena Pharmaceuticals; Ascend Therapeutics; Ascensia; Asklepion Pharmaceuticals; LLC; Aspen Pharmacare; Astellas; AstraZeneca; Atara Biotherapeutics; Avadel Pharmaceuticals; Avanir; Avant Healthcare; Avantor Performance Materials; Baxter Healthcare; Bayer; BioDelivery Sciences International; Biofrontera; Biogen; Boehringer Ingelheim; Bracco Diagnostics Inc.; Braeburn; B. Braun; Canopy Growth; Cara Therapeutics; Cascadia Drug Development Group; Catalyst Pharma; Celyad; Chiesi; Cipla; Cofactor Group; Consensus Orthopedics; CSL Behring; Daiichi Sankyo; DBV Tehcnologies; Deciphera Pharmaceuticals; Dendreon Pharmaceuticals LLC; DiaSorin; Eagle Pharmaceuticals; EHOB; Inc; Eisai; EMD Serono; eNeura Therapeutics; Ethypharm; EyePoint Pharmaceuticals; FerGene; Ferozsons Laboratories Limited; Ferring Pharmaceuticals; Frankel Advisory Group LLC; Galderma; GE Healthcare; Genmab; Getz Pharma; Greenwich Biosciences; Grifols; Grünenthal; Guerbet; Halloran Consulting Group; Helsinn; Horizon Therapeutics; IDbyDNA; Idorsia; Ipsen; Iridex; Ironwood; Joerns Healthcare; Johnson & Johnson; Kala Pharmaceuticals; Kaleo; Karyopharm Therapeutics; Kiniksa Pharmaceuticals; Kyowa Kirin; Leica Biosystems; LeMaitre Vascular; LEO Pharma; Lundbeck; Lupin; Mayne Pharma; Medacta USA; Medexus Pharmaceuticals; Medicure; MedinCell; MEDiSTRAVA; Medrobotics; Medtronic; Melinta Therapeutics; Merck; Merck KGaA; Milestone Pharmaceuticals; Mint Pharmaceuticals Inc.; Mirador Global LP; Mission Bio; Monebo Technologies; Nabriva Therapeutics; Nestle Health Science; Nevakar; NexGen Healthcare Communications; Nobio; Novartis; Novo Nordisk; Nuvisan; Ora; Osmotica Pharmaceuticals; OTSUKA; Panacea Biotec; Paratek Pharmaceuticals; Pfizer; Piramal Group; Prime Global; Proteus Digital Health; Purdue Pharma; QED Therapeutics; Retrophin; Rigel Pharmaceuticals; Roche; Samumed; Sandoz; Sanofi; Sanofi Genzyme; Sanofi Pasteur; Santen; Santhera Pharmaceuticals; Sarah Cannon; Scilex Pharmaceuticals; Servier; Shionogi Inc.; Sivantos Pte. Ltd.; SK Life Science; Smith & Nephew; SomaGenics Inc; Stgilesmedical London & Berlin; Straumann; Sumitovant BioPharma; Sunovion; Supernus; Surrozen; Syneos Health; Takeda Pharmaceuticals; Tecan; TerSera Therapeutics; TG Therapeutics; The Medical Affairs Company; The Stem; Theravance; Thermo Fisher Scientific; Think Surgical; Thompson Surgical Instruments; UCB Pharma; United BioSource; Vertex Pharmaceuticals; Vifor Pharma; ViiV Healthcare; Visioneering Technologies Inc.; Wellspect HealthCare; West 53rd St Digital; Worldwide Clinical Trials; XACT Robotics; XG Sciences; Zeiss Pharma; Zosano Pharma; Zydus Cadila

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.